drugset
drugset / Trial / NCT04103905

A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas

NCT04103905 ↗

Phase 1 Completed 27 enrolled Beijing Mabworks Biotech Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This open-label, multicenter,dose-escalating phase I study was designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma(NHL) for whom no treatment of higher priority was available.

Timeline

Start
2017-02-10
Primary completion
2019-05-30
Completion
2020-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject MIL62 Monoclonal antibody 200 mg Intravenous
Subject MIL62 Monoclonal antibody 400 mg Intravenous
Subject MIL62 Monoclonal antibody 800 mg Intravenous
Subject MIL62 Monoclonal antibody 1000 mg Intravenous
Subject MIL62 Monoclonal antibody 1500 mg Intravenous

Indications

B-cell non-Hodgkin lymphoma